Illumina Expands into Proteomics with $350 Million Acquisition of SomaLogic

Illumina to acquire SomaLogic for $350 million, expanding into proteomics and precision medicine. The deal includes SomaLogic's proteomics platform and other assets, strengthening Illumina's position in multi-omic analysis and precision medicine. The acquisition is expected to close later this year, pending regulatory approvals. This marks a strategic step for Illumina, a pioneer in genetic sequencing, to integrate genomic and proteomic data at scale, enabling truly personalized medicine.